Myeloma
CAR T-Cell Therapy Approved for Heavily Pretreated Multiple Myeloma
The FDA approved the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel, or cilta-cel, (Carvykti, ...
MARCH 1, 2022
COA: Paul Richardson, MD Discusses Myeloma Research
Paul Richardson, MD, professor of medicine at the Dana-Farber Cancer Institute, sat down with Clinical ...
JUNE 14, 2017
Shaji Kumar, MD, on Ventoclax Monotherapy for Multiple Myeloma
Dr. Kumar sat down with Clinical Oncology News to discuss his presentation, “Venetoclax Monotherapy for ...
FEBRUARY 7, 2017
OS Benefit Associated With Lenalidomide for Myeloma
Chicago—Maintenance lenalidomide extends the overall survival (OS) of patients with multiple myeloma by about ...
AUGUST 16, 2016
Daratumumab Receives Breakthrough Therapy Status for Multiple Myeloma
The therapy was granted breakthrough therapy status for use with either lenalidomide and dexamethasone or ...
AUGUST 9, 2016